Menu Search
Equities

GB Sciences Inc

18C:STU

GB Sciences Inc

Actions
  • Price (EUR)0.005
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change0.00%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

GB Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company. It creates patented, disease-targeted formulations of cannabis and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. (GBSGB). The primary focus for the development of its lead program has been in evaluating suitable development partners that will assist it in preparing its cannabinoid-based formulas for the treatment of the motor symptoms of Parkinson's disease in human clinical trials. It is engaged in the research and development of plant-inspired medicines, with virtual operations in North America and Europe. GBSGB’s has a portfolio of intellectual property containing both proprietary plant-inspired formulations and its artificial intelligence-enabled drug discovery platform, and critical research contracts and key supplier arrangements. Its intellectual property covers a range of 65 medical conditions.

  • Revenue in USD (TTM)0.00
  • Net income in USD-1.64m
  • Incorporated2018
  • Employees2.00
  • Location
    GB Sciences Inc6450 Cameron St Ste 110ALAS VEGAS 89118-4337United StatesUSA
  • Phone+1 (888) 895-3594
  • Websitehttps://gbsciences.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.